Pembrolizumab - Latest Advances

Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".

Journal: Cancer

Published: December 16, 2025

Head and Neck Cancer: A Review.

Journal: JAMA

Published: December 15, 2025

Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Journal: Future oncology (London, England)

Published: December 13, 2025

Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population.

Journal: Journal of medical economics

Published: December 13, 2025

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: December 12, 2025

Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.

Journal: JAMA ophthalmology

Published: December 11, 2025

Response to: Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: December 10, 2025

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition.

Journal: JAAD case reports

Published: December 09, 2025

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

Journal: BMJ open

Published: December 08, 2025

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

Journal: International journal of clinical pharmacology and therapeutics

Published: December 05, 2025

Development of Conjunctival Squamous Cell Carcinoma During Systemic Pembrolizumab Therapy for Laryngeal Cancer: A Case Report and Literature Review.

Journal: Ophthalmic plastic and reconstructive surgery

Published: December 04, 2025

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.

Journal: Hong Kong medical journal = Xianggang yi xue za zhi

Published: December 04, 2025

Filters

Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".

Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".

Head and Neck Cancer: A Review.

Head and Neck Cancer: A Review.

Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.

Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population.

Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population.

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.

Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.

Response to: Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort.

Response to: Pembrolizumab in advanced endometrial cancer: Dosing equivalence and molecular insights from an Asian cohort.

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition.

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition.

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom.

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab.

Development of Conjunctival Squamous Cell Carcinoma During Systemic Pembrolizumab Therapy for Laryngeal Cancer: A Case Report and Literature Review.

Development of Conjunctival Squamous Cell Carcinoma During Systemic Pembrolizumab Therapy for Laryngeal Cancer: A Case Report and Literature Review.

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.